137 related articles for article (PubMed ID: 24120784)
1. Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Richie JP
J Urol; 2013 Nov; 190(5):1767-8. PubMed ID: 24120784
[No Abstract] [Full Text] [Related]
2. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
[TBL] [Abstract][Full Text] [Related]
3. Curing metastatic cancer: lessons from testicular germ-cell tumours.
Masters JR; Köberle B
Nat Rev Cancer; 2003 Jul; 3(7):517-25. PubMed ID: 12835671
[TBL] [Abstract][Full Text] [Related]
4. Molecular targets for the treatment of testicular germ cell tumors.
Chieffi P
Mini Rev Med Chem; 2007 Jul; 7(7):755-9. PubMed ID: 17627586
[TBL] [Abstract][Full Text] [Related]
5. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
Harstrick A; Casper J; Schmoll HJ
Int J Androl; 1987 Feb; 10(1):139-45. PubMed ID: 3034790
[TBL] [Abstract][Full Text] [Related]
6. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
Schobert R; Biersack B; Dietrich A; Effenberger K; Knauer S; Mueller T
J Med Chem; 2010 Sep; 53(18):6595-602. PubMed ID: 20731355
[TBL] [Abstract][Full Text] [Related]
7. Growth and chemotherapy of a human germ-cell tumour line (GCT 27).
Schlappack OK; Bush C; Delic JI; Steel GG
Strahlenther Onkol; 1989 Jul; 165(7):541. PubMed ID: 2473535
[No Abstract] [Full Text] [Related]
8. [Cisplatin in the treatment of testicular carcinoma].
van Groeningen CJ; Pinedo HM
Ned Tijdschr Geneeskd; 1986 Nov; 130(44):1980-4. PubMed ID: 3022163
[No Abstract] [Full Text] [Related]
9. Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors.
Zschäbitz S; Lasitschka F; Jäger D; Grüllich C
Ann Oncol; 2016 Jul; 27(7):1356-60. PubMed ID: 27029705
[No Abstract] [Full Text] [Related]
10. Cisplatin-related Cerebral Infarction in Testicular Germ Cell Cancer: Short Report of Three Cases and P in testicular germ cell cancer: Short report of three cases and pathomechanism.
Lange J; Audebert HJ; Endres M; Rocco A
Clin Neurol Neurosurg; 2017 Jan; 152():76-77. PubMed ID: 27923208
[No Abstract] [Full Text] [Related]
11. Cisplatin related cardiotoxicity - acute and chronic cardiovascular morbidity in a testicular cancer survivor.
Morrow AJ; Cameron AC; Payne AR; White J; Lang NN
Scott Med J; 2020 Feb; 65(1):24-27. PubMed ID: 31886736
[No Abstract] [Full Text] [Related]
12. Cisplatin-based chemotherapy does not eliminate the risk of a second testicular cancer.
Fosså SD; Aass N
Br J Urol; 1989 May; 63(5):531-4. PubMed ID: 2543475
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.
Gerwing M; Jacobsen C; Dyshlovoy S; Hauschild J; Rohlfing T; Oing C; Venz S; Oldenburg J; Oechsle K; Bokemeyer C; von Amsberg G; Honecker F
J Cancer Res Clin Oncol; 2016 Sep; 142(9):1979-94. PubMed ID: 27424191
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
15. Ischemic stroke during cisplatin-based chemotherapy for testicular germ cell tumor: case report and review of the literature.
Meattini I; Scotti V; Pescini F; Livi L; Sulprizio S; Palumbo V; Sarti C; Biti G
J Chemother; 2010 Apr; 22(2):134-6. PubMed ID: 20435575
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary evaluation of cisplatin in the treatment of malignant testicular neoplasms other than seminomas].
Madej G; Zborzil J; Siedlecki P; Porwit-Ksiazek A
Pol Tyg Lek; 1981 Jun; 36(26):967-70. PubMed ID: 6270638
[No Abstract] [Full Text] [Related]
17. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Powles T; Shamash J; Berney D; Oliver RT
Br J Cancer; 2003 Sep; 89(6):1140-1; author reply 1141-2. PubMed ID: 12966438
[No Abstract] [Full Text] [Related]
19. Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.
Schaffrath J; Schmoll HJ; Voigt W; Müller LP; Müller-Tidow C; Mueller T
PLoS One; 2017; 12(6):e0178930. PubMed ID: 28591197
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin in germ cell testicular tumors (GCTT).
Germa Lluch JR
Prog Clin Biol Res; 1985; 203():381-9. PubMed ID: 2421332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
